Marksans Pharma has announced a record-breaking first quarter for FY27, with profitability reaching all-time highs and cash reserves exceeding ₹1,000 crore. The company reported a substantial increase in EBITDA and PAT, driven by strong revenue growth across its key markets, particularly in the UK and Europe. This performance positions Marksans for continued organic and inorganic growth.
Marksans Pharma Reports Record Q1 FY27 Financial Results
Marksans Pharma Ltd. has delivered a robust performance in the first quarter of fiscal year 2027 (Q1 FY27), ending June 30, 2026. The company announced record profitability at all-time highs and crossed the ₹1,000 crore mark in cash reserves for the first time, closing the quarter with ₹1,058 crore.
Key Financial Highlights
The company’s financial results for Q1 FY27 showcase significant year-over-year growth:
- Operating Revenue: Increased by 35.6% YoY to ₹841 crore.
- Gross Profit: Rose by 38.9% YoY to ₹497 crore, with a gross margin of 59.1%.
- EBITDA: Grew by 112.8% YoY to ₹213 crore, achieving an EBITDA margin of 25.3%.
- PAT (Profit After Tax): Spiked by 173.9% YoY to ₹159 crore, with a net margin of 18.4%.
- EPS (Earnings Per Share): Stood at ₹3.5.
Geographic Performance and Business Highlights
UK & Europe Market: This region achieved its highest-ever quarterly revenue of ₹356 crore, a 74.7% YoY increase. The acquisition of QliniQ B.V. contributed ₹44 crore to the Q1 FY27 revenue, marking a significant step in European expansion. The market shows strong potential for future growth.
US & North America Market: The formulation business reported revenues of ₹377 crore, up 15.1% YoY. This remains the largest market, contributing approximately 45% of consolidated revenue, supported by a healthy order book and new product launches.
Australia & New Zealand Market: Revenues grew by 53.7% YoY to ₹88 crore, driven by portfolio expansion and new product introductions.
Rest of World (RoW) Market: Reported revenues of ₹20 crore, showing a sequential improvement after four quarters of decline.
Strategic Initiatives and Outlook
Mark Saldanha, Managing Director, highlighted the company’s strong start to the year, emphasizing the record EBITDA and PAT as indicators of underlying business strength and focus on profitable growth. The company also successfully completed the acquisition of 100% of QliniQ B.V. and ABCnow in Europe. Looking ahead, Marksans Pharma aims to scale its businesses across geographies, accelerate new product launches, and further strengthen its European platform, with a clear focus on sustainable growth driven by broad-based growth, expanding margins, and a strong balance sheet.
Other Highlights:
- Cash generated from operations: ₹185 crore.
- Net Capex: ₹33 crore, resulting in a free cash flow of ₹152 crore.
- Working capital cycle improved to approximately 132 days from 159 days in Q1 FY26.
- Cash balance: ₹1,058 crore as of June 30, 2026.
- Net cash: ₹1,031 crore.
- R&D spends: ₹23 crore, representing 2.8% of consolidated revenue.
- India Ratings and Research revised the company’s bank loan facilities outlook to Positive from Stable, affirming ratings at IND AA-/IND A1+.
An earnings conference call is scheduled for August 13, 2026, at 4:30 pm IST to discuss these results.
Source: BSE
